Details of the Drug

General Information of Drug (ID: DMANKTO)

Drug Name
Vatreptacog alfa (activated)
Synonyms NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk
Indication
Disease Entry ICD 11 Status REF
Bleeding disorder GA20-GA21 Phase 3 [1]
Cross-matching ID
TTD ID
D00VMA

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor VII (F7) TTF0EGX FA7_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Bleeding disorder
ICD Disease Classification GA20-GA21
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Coagulation factor VII (F7) DTT F7 2.52E-01 -0.03 -0.19
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01392547) Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors. U.S. National Institutes of Health.
2 Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.